The oncologist · 2025
Utility and real-world clinical outcomes of next-generation sequencing in advanced non-small-cell lung cancer in the South Indian population.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Anoop Thattungal Manoharan, Raj Lakshmi, Nair Pallavi, Vincent Athira
Аннотация
BACKGROUND: Next-generation sequencing (NGS) is an advanced sequencing technology that enables rapid sequencing of numerous DNA strands and performs simultaneous analysis of various genes and diverse genomic characteristics. While there is a lack of substantial evidence available, the extent to which NGS may improve clinical outcomes among cancer patients in a real-world scenario remains uncertain.
OBJECTIVE: To investigate the clinical utility of NGS in patients treated with advanced non-small cell lung cancer (NSCLC) and its impact on real-world clinical outcomes, treated with targetable or non-targetable agents.
MATERIALS AND METHODS: This was a prospective observational study conducted in 322 participants distributed over 2 broad categories- NGS and non-NGS. The NGS category consisted of patients who underwent genetic mutation screening by the NGS method. This group was further categorized into 2 subgroups-NGS-targetable and NGS-non-targetable. The non-NGS category consisted of patients who did not undergo mutation testing by the NGS method.
RESULTS: There was a significant difference in overall survival between NGS and non-NGS groups (P = .0038). There was a significant difference between NGS targetable and non-targetable groups in terms of progression-free survival (PFS; P = .0016) and overall survival (OS; P < .0001). There was a significant difference between NGS-matched and non-matched groups in terms of PFS (P < .00011) as well as OS (P < .0001).
CONCLUSIONS: NGS significantly improved survival in advanced NSCLC. Patients who received treatments matched to their NGS results experienced significantly longer survival compared to those with non-matched treatments.
OBJECTIVE: To investigate the clinical utility of NGS in patients treated with advanced non-small cell lung cancer (NSCLC) and its impact on real-world clinical outcomes, treated with targetable or non-targetable agents.
MATERIALS AND METHODS: This was a prospective observational study conducted in 322 participants distributed over 2 broad categories- NGS and non-NGS. The NGS category consisted of patients who underwent genetic mutation screening by the NGS method. This group was further categorized into 2 subgroups-NGS-targetable and NGS-non-targetable. The non-NGS category consisted of patients who did not undergo mutation testing by the NGS method.
RESULTS: There was a significant difference in overall survival between NGS and non-NGS groups (P = .0038). There was a significant difference between NGS targetable and non-targetable groups in terms of progression-free survival (PFS; P = .0016) and overall survival (OS; P < .0001). There was a significant difference between NGS-matched and non-matched groups in terms of PFS (P < .00011) as well as OS (P < .0001).
CONCLUSIONS: NGS significantly improved survival in advanced NSCLC. Patients who received treatments matched to their NGS results experienced significantly longer survival compared to those with non-matched treatments.